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2Key points
•  A high incidence of colorectal tumors was recently reported in patients with
Birt-Hogg-Dubé syndrome (BHD), implicating a potential role for the BHD
gene in colorectal tumorigenesis.
•  We have screened the BHD gene for genetic (mutations and loss of
heterozygosity (LOH)) and epigenetic (altered promoter methylation status)
alterations in 47 unselected primary sporadic colorectal tumors (10 polyps and
37 carcinomas).  One polyp and 7 carcinomas demonstrated microsatellite
instability (MSI) while all other tumors were microsatellite stable (MSS).
•  We identified two novel missense mutations, S79W and A445T, in two MSS
carcinomas.  Methylation status, examined by methylation specific PCR (MSP)
analysis of 23 matched normal/carcinoma tissues showed an absence of any
BHD promoter methylation differences.
•  Genotyping of microsatellite markers encompassing the BHD gene showed LOH
in 4 of 10 (40%) polyps and 29 of 36 (81%) carcinomas.  All 4 colon polyps
showing LOH demonstrated chromosomal loss in the corresponding carcinomas
from the same patients.  However, LOH was also present in the corresponding
carcinomas of 6 other polyps that did not show LOH, suggesting the
involvement of LOH in colorectal tumor progression.
•  Our results suggest that the BHD gene is involved in the tumorigenesis of a
subset of MSS sporadic colorectal carcinomas, and that allelic loss in the region
close to the BHD gene may play a role in colorectal tumor progression.
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3Colorectal cancer (CRC) is the third most common cancer diagnosed in both men and
women, and the second most common cause of cancer deaths in the United States.
There were approximately 150,000 new cases resulting in 57,000 deaths in 2002 [1].
CRC is one of the most studied cancer types and its underlying etiology best elucidated.
Colorectal tumorigenesis involves a multi-step process including genetic and epigenetic
alterations of numerous CRC-related genes that may act as either oncogenes or tumor
suppressor genes [2-5].  The majority of sporadic CRCs are characterized by deletions
of large chromosomal segments, which is thought to represent the loss of wild-type
tumor suppressor genes [6, 7].  About 15% of sporadic CRCs, on the other hand, are
show microsatellite instability (MSI), characterized by the insertion and/or deletion of
simple-repeat sequences and indicative of the involvement of defective mismatch repair
[8-9].
Birt-Hogg-Dubé syndrome (BHD, OMIM 135150) is an inherited autosomal dominant
syndrome characterized by a triad of cutaneous lesions consisting of fibrofolliculomas,
trichodiscomas, and acrochordons [10].  A wide spectrum of neoplastic and non-
neoplastic features has been described in BHD patients [11], including diverse types of
kidney tumors [12-17] and spontaneous pneumothorax [12-16, 18].  BHD has also been
reported to be associated with colonic polyposis and colorectal neoplasia [13, 19-22],
although a large study of 223 patients from 33 BHD families could not establish such a
relation [23].  We recently reported a high incidence of colorectal polyps and
carcinomas in patients with confirmed BHD germline mutations, indicating that the
BHD gene may be involved in colorectal tumorigenesis [13].  The BHD gene has been
mapped to chromosome sub-band 17p11.2 [12, 14], and recently identified to encode a
novel protein named follicullin [15].  Based on the presence of inactivating BHD
4mutations in BHD patients, and the detection of LOH in a significant proportion of
BHD-related tumors, the BHD gene was considered to be a tumor suppressor gene.  A
44% frequency of frameshift mutations within a mononucleotide (C)8 tract (nt
1733–1740) has been detected in BHD patients [15], and this repeat tract represents a
BHD mutational hot spot [13, 15].  Other studies have reported the presence of
frameshift mutations within intragenic mononucleotide tracts of the TGFBR2 and BAX
genes in CRC cell lines and tumors with high level MSI [24, 25].  The poly C tract of
the BHD gene may therefore be a potential site of mutation in CRC characterized by
MSI.
We have evaluated the role of the BHD gene in 47 unselected colorectal tumors (10
polyps and 37 carcinomas) by screening all coding exons of the BHD gene for
mutations and analyzing 46 of the tumors for LOH at the chromosome region
surrounding the BHD locus.  Furthermore, alterations in BHD promoter methylation
profiles were determined in 23 cases of matched normal/carcinoma tissues where a
sufficient quantity of DNA was available.  We report the detection of 2 novel somatic
missense mutations of the BHD gene and LOH in 81% of primary sporadic colorectal
tumors with no change in promoter methylation profile. All mutations were detected in
MSS tumors.
5MATERIALS AND METHODS
Tissue samples and DNA extraction
Forty-seven matched samples (from 37 patients), of which 10 were colonic polyps with
their matched carcinomas from the same patients, and 37 colorectal carcinomas, were
obtained from the South Western Sydney Colorectal Tumour Bank (Liverpool Hospital,
Australia).  All tissue samples were collected prospectively with the informed consent
of patients who underwent surgery in the South Western Sydney Area Health Service
during the period 2000-2002.  The lack of a family history of colorectal cancer or other
familial cancer syndrome was ascertained by detailed questionnaire.  This study was
approved by the Institutional Review Board of the Van Andel Research Institute.
Frozen sections (15 m m) were prepared from stored tumor specimens.  The first, middle
and last slides (5 m m) were stained as reference slides.  Manual microdissection was
carried out on the unstained slides under low power light microscopy (20-40X) by
scraping of individual cell populations with a 28-gauge needle.  DNA was isolated from
microdissected tumor cells and specimens of normal colonic mucosa using the Qiagen
DNeasy Mini system (Qiagen, Valencia, CA), according to the manufacturer’s
instructions.  DNA was extracted from peripheral blood leukocytes using the DNA
isolation kit for mammalian blood (Roche Molecular Biochemicals).
Analysis of microsatellite instability (MSI) status
Paired colorectal carcinoma, polyp and constitutional DNA samples (n=47) were
analyzed using a panel of 10 microsatellite markers comprising mononucleotide
(BAT25, BAT26), dinucleotide (D2S123, D5S346, D18S34, D3S1611), and
tetranucleotide (D1S518, D7S1808, D3S2432, D10S1426) repeats.  Amplification was
6performed in a final volume of 10 m l containing 25 ng DNA, 20 pmol each primer, 16
m M dATP, 0.2 mM remaining dNTPs, 0.4 m Ci of a -33P [dATP], 50 mM KCl, 10 mM
Tris-HCl (pH 8.3), 1.5 mM MgCl2 and 0.5 U Taq polymerase (Amersham-Pharmacia
Biotech).  PCR was initiated by a 5 min denaturation (94 ºC) followed by 34 cycles of
denaturation (94 ºC, 45 s), primer annealing (55-65 ºC, 45 s) and extension (72 ºC, 45
s).  PCR cycling was ended with a 10 min extension (72 ºC) step.  Radio isotope-labeled
PCR products were electrophoresed on 6% sequencing gels and visualized by
autoradiography.  Samples were classified as MSI-L (low level microsatellite
instability) if instability was observed at 20–40% of loci assayed or MSI-H (high level
microsatellite instability) if instability was observed at over 40% of loci assayed [26].
Mutation analysis
Mutation screening was performed on all 47 matched samples.  The entire coding
region of the BHD gene (exons 4–14) was screened.  Primer sequences and PCR
conditions were according to Nickerson et al. [14].  PCR was performed using a DNA
Engine Tetrad (MJ Research, Waltham, MA).  PCR products were analyzed on standard
1.5% agarose gels stained with ethidium bromide (0.5 m g/ml) before purification with
Multiscreen PCR cleanup plates (Millipore, Molsheim, France).  Sequencing reactions
were performed using the Big Dye Terminator system (Applied Biosystems, Foster
City, CA), purified through Sephadex G-50 (Amersham Biosciences, Uppsala, Sweden)
and analyzed on an ABI 3700 genetic analyzer (Applied Biosystems).  We aligned and
analyzed all sequences by Blast 2 analysis [27] and manually verified all sequences
again.  All sequence changes were verified by reamplification of the corresponding
BHD fragment and sequencing of both DNA strands.
7Analysis of loss of heterozygosity (LOH) status
LOH was performed on 36 matched normal/tumor tissue pairs, as well as 10 matched
normal/polyp pairs.  Allelic deletions of the chromosome 17p region flanking the BHD
gene were assessed using microsatellite markers D17S1857, D17S740, D17S2196, and
D17S620.  The relative distances between each marker and their relationship to the
BHD gene were calculated using the UCSC Genomic Bioinformatics site (fig. 1).  PCR
conditions were according to Khoo et al. [13].  One microliter of each PCR product was
added to a cocktail containing 5 m l of DNAse-free, RNAse-free distilled water, 10 m l of
Hi-Di formamide and 0.2 m l of ROX 400HD size standard.  The mixture was denatured
at 95ºC for 5 min before loading into an ABI Prism 3700 Genetic Analyzer (Applied
Biosystems).  Analysis of raw data and assessment of LOH were carried out using
Genescan v. 3.7 and Genotyper v. 3.7 software (Applied Biosystems).  LOH was
defined according to the following formula: LOH index = (T2/T1)/(N2/N1), where T
was the tumor sample, N was the matched normal sample, 1 and 2 were the intensities
of smaller and larger alleles, respectively [28].  If the ratio was < 0.67 or > 1.3, the
result was determined to be LOH.  Initially, the 2 closest markers (D17S740 and
D17S2196) were analyzed for LOH.  A designation of LOH was given when at least
one of the markers had a ratio that was < 0.67 or > 1.3.  If the LOH value was close to
these thresholds (0.67 + 0.1; 1.3 – 0.1), a further two markers, D17S1857 and D17S620,
were examined to confirm the LOH status.
Analysis of BHD promoter methylation profile
We examined the promoter methylation status of the BHD gene in 23 matched
normal/carcinoma sample sets.  DNA methylation status was determined by a
methylation-specific PCR approach (MSP) [29, 30].  DNA was treated with sodium
8bisulfite, which converts all unmethylated cytosines to uracils, leaving methylated
cytosines unchanged.  Briefly, 2 m g of DNA was denatured by incubation in 0.2 M
NaOH (37 ºC, 10 min).  Cytosines were then modified in 3 M sodium bisulfite (adjusted
to pH 5.0; Sigma Chemical Co., St. Louis, MO) and 10 mM hydroquinone (Sigma) at
50 ºC for 16 h.  DNA samples were then purified through columns (Microcon YM-100;
Millipore, Bedford, MA), treated again in 0.3 M NaOH, precipitated with ethanol using
glycogen as a carrier, and resuspended in 20 m l DNAse-free, RNAse-free distilled water
before storing at -20ºC.  The specific primers for methylated sequences were designed
as follows: BHD-BISF-OF (5'-ATGTGGATAGGAAGTTTTAGGTTGGTTATATTT-
3') as the forward primer, and BHD-BISF-OR (5'
ACAAAATCACACCCAAAACCCCC-3') as the reverse primer.  An aliquot of the
bisulfite treated product (2 m l) was amplified in a 25 m l reaction containing 2 mM
MgCl2, 0.24 mM each dNTP (Invitrogen), 0.02 U Taq DNA polymerase (Invitrogen)
and 0.1 m M of each primer.  PCR conditions were 95 ºC for 5 min followed by 35
cycles of 94 ºC (30 s), 60 ºC (30 s), and 72 ºC (45 s). PCR was ended with a 7 min
extension (72 ºC).  A nested PCR was then performed using 1 m l of the initial
amplification reaction.  The primers used were BHD-BISF-IF: 5'-
GAAATGGTTTTTTTTAGTATTTTTAGTTGGTG-3' and BHD-BISF-IR: 5'-
CCCAAAACCCCCAAACCCA-3', with conditions similar to those described for the
preceding PCR amplification, with the exception that 40 amplification cycles were
carried out.  The PCR products were purified using Microcon YM-100 columns
(Millipore).  After amplification, 20 m l of the 414 bp PCR product was incubated with
0.3 U of RsaI (New England BioLabs, Inc., Beverly, MA) for 2 h at 37 ºC.  l DNA (0.3
m g) and distilled water were used respectively as positive and negative controls.
Products of restriction digestion (20 m l) were electrophoresed on 2% agarose gels
9containing ethidium bromide, and visualized under UV illumination.  The sizes of the




Analysis of MSI status showed that 8 of 47 tumors tested demonstrated MSI (table 1).
This represents approximately 17% of the sporadic colorectal tumor cases evaluated in
this study.  Five carcinomas (CRC-7, CRC-17, CRC-18, CRC-46, and CRC-52) showed
high frequency of MSI (MSI-H), while 2 carcinomas (CRC-23 and CRC-42) exhibited
low frequency of MSI (MSI-L).  CRC-42 also demonstrated low level of MSI in its
corresponding polyp (42P).  All other tumors (39 of 47) were microsatellite stable
(MSS).
BHD Mutations
Screening of the BHD coding region identified 2 novel somatic mutations in exon 4
(c.691C>G) and exon 12 (c.1788G>A) of CRC-28 and CRC-54, respectively (table 1,
fig. 2).  Both are missense mutations (S79W and A445T), leading to nonconservative
amino acid changes.  In both cases the carcinomas were MSS and tumors with BHD
mutations represented approximately 7% of the MSS colorectal carcinomas tested
(n=30).  No mutations were detected in the (C)8 repeat tract (nt 1733–1740), known to
be a mutational hot spot within the BHD gene, in either the MSI or MSS tumors.  BHD
mutations were absent in all colon polyps.
LOH status
LOH at the chromosomal region surrounding the BHD locus was identified in 81% (29
of 36) of the sporadic colorectal carcinomas, and 40% (4 of 10) of colon polyps (table
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1).  The 4 colon polyps with LOH were from the same individuals who showed LOH in
their colorectal carcinomas (CRC-34, 34P; CRC-42, 42P; CRC-56, 56P; and CRC-59,
59P).  CRC-28 demonstrated LOH, along with somatic mutation S79W.
BHD promoter methylation
Methylation specific PCR analysis of the BHD promoter did not detect any promoter
methylation profile differences in the 23 matched sets tested (table 1).  Unfortunately,
methylation profiles for the rest of the samples could not be determined due to
insufficient DNA being available.
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DISCUSSION
Early studies have reported several cases of colorectal neoplasia in patients with BHD
[19-22].  However, one recent study [23] showed a lack of statistical significance when
comparing the incidence of colon cancer in 111 BHD-affected and 112 BHD-unaffected
subjects, as well as the occurrence of colon polyps in 45 BHD-affected and 38 BHD-
unaffected subjects, thus excluding any association between colonic neoplasia and
BHD.  Nevertheless, we recently reported 6 cases of colonic polyps and 2 cases of
possible colon cancer in a BHD family with confirmed BHD germline mutations [13],
indicating that the BHD gene is involved in the tumorigenesis of these BHD-related
colorectal tumors.  In this study, we demonstrate that the BHD gene is also involved in a
subset of sporadic colorectal cancers.  Two cases of MSS colorectal cancer were found
to harbor two novel somatic missense mutations, S79W and A445T, in exons 4 and 12,
respectively.  Interestingly, no frameshift mutation was identified in the hypermutable
poly C tract, particularly in the MSI carcinomas, as this region is a potential site for
insertion or deletion in cancers with defective mismatch repair.  These results suggest
that the BHD gene may be involved in a pathway of colorectal tumorigenesis that is
distinct from the pathway of mismatch repair deficiency.  However, the sample size of
the MSI tumors is small in this series and further investigation is warranted.
The detected missense mutations where nonconservative amino acid substitutions
(S79W and A445T) in the BHD gene product which could cause conformational
changes in the structure of the protein, leading to dysfunction [31-35].  Protein
phosphorylation, a modulator of protein function and stability, can occur at Ser, Thr or
Tyr residues and is mediated by specific protein kinases.  In CRC-28, the change from
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Ser to Trp leads to the loss of a potential site of phosphorylation whereas the Ala to Thr
change in CRC-54 leads to the gain of a potential phosphorylation site.  These amino
acid changes could lead to altered protein phosphorylation status with consequent
functional changes.
LOH, which indicates the loss of one functional copy of a gene, has been used as a
marker for diagnosis and prognosis of cancer.  In this study, we identified LOH at
microsatellite loci flanking the BHD gene in 40% of colon polyps and 81% of colorectal
carcinomas.  Together with the finding of LOH in matched normal/carcinoma samples
of LOH negative polyps, we propose that LOH surrounding the BHD locus may be
involved in colorectal cancer progression, although other tumor suppressor genes
located on chromosome 17p, such as p53, should not be excluded.  The p53 gene is
located approximately 9 cM telomeric to the BHD gene.  Studies have shown that LOH
at 17p may be essential for the malignant transformation of benign lesions in colorectal
neoplasms [36, 37].  Therefore, the effects of LOH on BHD gene expression and
regulation in colorectal tumors merits further investigation.
Sample CRC-28 was found to harbor a mutation in the BHD gene as well as LOH
around the BHD region, which could represent two hits of the BHD gene in accordance
with Knudson’s classical 2-hit theory.  Apparent biallelic alteration of the BHD gene
appears to be uncommon and the high frequency of LOH in the rest of tumors without
mutations suggests several possibilities.  First, loss of a single allele may be the
preferred mode of inactivation of the BHD gene and that haploinsufficiency contributes
to tumorigenesis.  Second, there may be mutations present in the regulatory region of
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the BHD gene that was not tested in this study.  Finally, there may be loss of other
tumor suppressor genes in the vicinity of the BHD gene.
DNA methylation is an epigenetic alteration that interferes with transcriptional
initiation.  In general, methylation of CpG dinucleotides in the promoter regions of
tumor suppressor genes leads to loss of tumor suppressor gene expression (silencing)
and consequent function.  Hypermethylation of tumor suppressor genes has been
frequently reported in many tumor types.  We recently identified the involvement of the
BHD gene in sporadic renal tumors by showing frequent methylation of the BHD
promoter in a wide spectrum of sporadic renal tumors [38].  In the present study, we did
not detect any BHD promoter methylation profile differences in the 23 colorectal
carcinoma cases where a sufficient amount of DNA was available for the MSP assay.
We conclude that epigenetic alteration of the BHD gene is not a common event in
colorectal cancer.
In summary, we have demonstrated that the BHD gene is mutated in a subset of MSS
sporadic colorectal carcinomas, and allelic loss around the region of the gene may play
a role in the progression of colorectal tumors.
15
Acknowledgements
This study was supported by the Van Andel Foundation
16
REFERENCES
1.Jemal A, Thomas A, Murray T, Thun M.  Cancer Statistics, 2002.  Ca Cancer J Clin
2002; 52: 23-47.
2.Bos JL, Fearon ER, Hamilton SR, Verlaan-de Vries M, van Boom JH, van der Eb AJ,
Vogelstein B.  Prevalence of ras gene mutations in human colorectal cancers.  Nature
1987; 327: 293-7.
3.Baker SJ, Fearon ER, Nigro JM, Hamilton SR, Preisinger AC, Jessup JM, van Tuinen
P, Ledbetter DH, Barker DF, Nakamura Y, White R, Vogelstein B.  Chromosome 17
deletions and p53 gene mutations in colorectal carcinomas.  Science 1989; 244: 217-21.
4.Fearon ER, Cho KR, Nigro JM, Kern SE, Simons JW, Ruppert JM, Hamilton SR,
Preisinger AC, Thomas G, Kinzler KW, Vogelstein B.  Identification of a chromosome
18q gene that is altered in colorectal cancers.  Science 1990; 247: 49-56.
5.Kinzler KW, Nilbert MC, Vogelstein B, Bryan TM, Levy DB, Smith KJ, Preisinger
AC, Hamilton SR, Hedge P, Markham A, Carlson M, Joslyn G, Groden J, White R,
Miki Y, Miyoshi Y, Nishisho I, Nakamura Y.  Science 1991; 251: 1366-70.
6.Lengauer C, Kinzler KW, Vogelstein B.  Genetic instabilities in human cancers.
Nature 1998; 396: 643-9.
7.Martin L, Assem M, Piard F.  Are there several types of colorectal carcinomas?
Correlations with genetic data.  Eur J Cancer Prev  1999; 8: S13-20.
17
8.Thibodeau SN, Bren G, Schaid D.  Microsatellite instability in cancer of the proximal
colon.  Science 1993; 260: 816-9.
9.Ionov Y, Peinado MA, Malkhosyan S, Shibata D, Perucho M.  Ubiquitous somatic
mutations in simple repeated sequences reveal a new mechanism for colonic
carcinogenesis.  Nature 1993; 363: 558-61.
10.Birt AR, Hogg GR, Dubé WJ.  Hereditary multiple fibrofolliculomas with
trichodiscomas and acrochordons.  Arch Dermatol  1977; 113: 1674-7.
11.Schulz T, Hartschuh W.  Birt-Hogg-Dubé syndrome and Hornstein-Knickenberg-
syndrome are the same.  Different sectioning techniques as the cause of different
histology.  J Cutan Pathol  1999; 26: 55-61.
12.Khoo SK, Bradley M, Wong FK, Hedblad M-A, Nordenskjöld M, Teh BT.  Birt-
Hogg-Dubé syndrome: mapping of a novel hereditary neoplasia gene to chromosome
17p12-q11.2.  Oncogene  2001; 20: 5239-42.
13.Khoo SK, Giraud S, Kahnoski K, Chen J, Motorna O, Nickolov R, Binet O, Lambert
D, Friedel J, Lévy R, Ferlicot S, Wolkenstein P, Hammel P, Bergerheim U, Hedblad M-
A, Bradley M, Teh BT, Nordenskjöld M, Richard S.  Clinical and genetic studies of
Birt-Hogg-Dubé syndrome.  J Med Genet  2002; 39: 906-12.
18
14.Schmidt LS, Warren MB, Nickerson ML, Weirich G, Matrosova V, Toro JR, Turner
ML, Duray P, Merino M, Hewitt S, Pavlovich CP, Glenn G, Greenberg CR, Linehan
WM, Zbar B.  Birt-Hogg-Dubé syndrome, a genodermatosis associated with
spontaneous pneumothorax and kidney neoplasia, maps to chromosome 17p11.2.  Am J
Hum Genet  2001; 69: 876-82.
15.Nickerson ML, Warren MB, Toro JR, Matrosova V, Glenn G, Turner ML, Duray P,
Merino M, Choyke P, Pavlovich CP, Sharma N, Walther M, Munroe D, Hill R, Maher
E, Greenberg C, Lerman MI, Linehan WM, Zbar B, Schmidt LS. Mutations in a novel
gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in
patients with the Birt-Hogg-Dubé syndrome. Cancer Cell  2002; 2: 157-64.
16.Roth JS, Rabinowitz AD, Benson M, Grossman ME.  Bilateral renal cell carcinoma
in the Birt-Hogg-Dubé syndrome.  J Am Acad Dermatol   1993; 29: 1055-6.
17.Toro J, Glenn G, Duray P, Darling T, Weirich G, Zbar B, Linehan M, Turner M.
Birt-Hogg-Dubé syndrome: a novel marker of kidney neoplasia.  Arch Dermatol  1999;
135: 1195-202.
18.Chung JY, Ramos-Caro FA, Beers B, Ford MJ, Flowers F.  Multiple lipomas,
angiolipomas and parathyroid adenomas in a patient with Birt-Hogg-Dubé syndrome.
Int J Dermatol  1996; 35: 365-7.
19.Hornstein OP.  Generalized dermal perifollicular fibromas with polyps of the colon.
Hum Genet  1976; 33: 193-7.
19
20.Binet O, Robin J, Vicart M, Ventura G, Beltzer-Garelly E.  Fibromes
périfolliculaires, polypose colique familiale, pneumothorax spontanés familiaux.  Ann
Dermatol Venereol  1986; 113: 928-30.
21.Rongioletti F, Hazini R, Gianotti G, Rebora A.  Fibrofolliculomas, tricodiscomas
and acrochordons (Birt-Hogg-Dubé) associated with intestinal polyposis.  Clin Exp
Dermatol  1989; 14: 72-4.
22.Sasai S, Takahashi K, Tagami H.  Coexistence of multiple perifollicular fibromas
and colonic polyp and cancer.  Dermatology  1996; 192: 262-3.
23.Zbar B, Alvord WG, Glenn G, Turner M, Pavlovich CP, Schmidt L, Walther M,
Choyke P, Weirich G, Hewitt SM, Duray P, Gabril F, Greenberg C, Merino MJ, Toro J,
Linehan WM.  Risk of renal and colonic neoplasms and spontaneous pneumothorax in
the Birt-Hogg-Dubé syndrome.  Cancer Epidemiol Biomarkers Prev  2002; 11: 393-
400.
24.Markowitz S, Wang J, Myeroff L, Parsons R, Sun L, Lutterbaugh J, Fan RS,
Zborowska E, Kinzler KW, Vogelstein B, Brattain M, Willson JKV.  Inactivation of the
type II TGF-beta receptor in colon cancer cells with microsatellite instability.  Science
1995; 268: 1336-8.
25.Rampino N, Yamamoto H, Ionov Y, Li Y, Sawai H, Reed JC, Perucho M.  Somatic
frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator
phenotype.  Science  1997; 275: 967-9.
20
26.Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW,
Meltzer SJ, Rodriguez-Bigas MA, Fodde R, Ranzani GN, Srivastava SA.  National
Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial
predisposition: development of international criteria for the determination of
microsatellite instability in colorectal cancer.  Cancer Res  1998; 58: 5248-57.
27.Tatusova TA, Madden TL.  Blast 2 sequences - a new tool for comparing protein and
nucleotide sequences.  FEMS Microbial Lett  1999; 174: 247-50.
28.Giraud S, Choplin H, Teh BT, Lespinasse J, Lenoir G, Hamon P, Calender A.  A
large MEN1 family with clinical expression suggestive of anticipation.  J Clin
Enodcrinol Metab  1997; 82: 3487-92.
29.Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB.  Methylation-specific
PCR: a novel PCR assay for methylation status of CpG islands.  Proc Natl Acad Sci
USA  1996; 93: 9821-6.
30.Esteller M, Herman JG.  Cancer as an epigenetic disease: DNA methylation and
chromatin alterations in human tumours.  J Pathol  2002; 196: 1-7.
31.Brennan SO, Maghzal G, Shneider BL, Gordon R, Magid MS, George PM.  Novel
fibrinogen gamma 375 ArgàTrp mutation (fibrinogen aguadilla) causes hepatic
endoplasmic reticulum storage and hypofibrinogemia.  Hepatology  2002; 36: 652-8.
21
32.Topalian SL, Gonzales MI, Ward Y, Wang X, Wang RF.  Revelation of a cryptic
major histocompatibility complex class II-restricted tumor epitope in a novel RNA-
processing enzyme.  Cancer Res  2002; 62: 5505-9.
33.Tsukaguchi H, Sudhakar A, Le TC, Nguyen T, Yao J, Schwimmer JA, Schachter
AD, Poch E, Abreu PF, Appel GB, Pereira AB, Kalluri R, Pollak MR.  NPHS2
mutations in late-onset focal segmental glomerulosclerosis: R229Q is a common
disease-associated allele.  J Clin Invest  2002; 110: 1659-66.
34.Asada-Senju M, Maeda T, Sakata T, Hayashi A, Suzuki T.  Molecular analysis of the
transferring gene in a patient with hereditary hypotransferrinemia.  J Hum Genet  2002;
47: 355-9.
35.Dhitavat J, Marfarlane S, Dode L, Leslie N, Sakuntabhai A, MacSween R, Saihan E,
Hovnanian A.  Acrokeratosis verruciformis of Hopf is caused by mutation in ATP2A2:
evidence that it is allelic to Darier’s disease.  J Invest Dermatol  2003; 120: 229-32.
36.Boland CR, Sato J, Appelman HD, Bresalier RS, Feinberg AP.  Microallelotyping
defines the sequences and tempo of allelic losses at tumor suppressor gene loci during
colorectal cancer progression.  Nat Med  1995; 1: 902-9.
37.Yashiro M, Carethers JM, Laghi L, Saito K, Slezak P, Jaramillo E, Rubio C,
Koizumi K, Hirakawa K, Boland CR.  Genetic pathways in the evolution of
morphologically distinct colorectal neoplasms.  Cancer Res  2001; 61: 2676-83.
22
38.Khoo SK, Kahnoski K, Sugimura J, Petillo D, Chen J, Shockley K, Ludlow J, Knapp
R, Giraud S, Richard S, Nordenskjöld M, Teh BT.  Inactivation of BHD in sporadic




Schematic map of microsatellite markers encompassing the BHD gene.  The relative
distances (in cM) between each marker and their relationship to the BHD locus are
indicated.
Figure 2
Detection of mutations within the BHD gene in sporadic colorectal cancer.  Two novel
somatic mutations of the BHD gene were detected in two MSS colorectal carcinomas.
Each of the mutations is not present in the matched normal tissues.  (A) c.691C>G
(S79W) in CRC-28 and (B) c.1788G>A (A445T) in CRC-54.
Table 1  MSI and inactivation profiles of the BHD gene in sporadic colorectal carcinomas and polyps  
  Sample ID MSI Status BHD Mutation LOH Methylation  
            CRC-1 – – + ND  
            CRC-2 – – + ND  
            CRC-3 – – – ND  
            CRC-4 – – ND ND  
            CRC-6 – – + –  
            CRC-7 + (H) – + ND  
            CRC-9 – – + –  
            CRC-12 – – + ND  
            CRC-13 – – – –  
            CRC-14 – – + ND  
            CRC-17 + (H) – + –  
            CRC-18 + (H) – – ND  
            CRC-19 – – + ND  
            CRC-20 – – + ND  
            CRC-22 – – + ND  
            CRC-23 + (L) – + ND  
            23P – – – ND  
            CRC-28 – S79W + –  
            CRC-30 – – + –  
            CRC-31 – – + –  
            CRC-34 – – + ND  
            34P – – + ND  
            CRC-35 – – + –  
            35P – – – ND  
            CRC-37 – – + ND  
            37P – – – ND  
            CRC-38 – – – –  
            CRC-42 + (L) – + –  
            42P + (L) – + ND  
            CRC-43 – – + –  
            43P – – – ND  
            CRC-44 – – + –  
            44P – – – ND  
            CRC-45 – – + –  
            CRC-46 + (H) – – –  
            CRC-48 – – + –  
            CRC-49 – – + –  
            CRC-50 – – + –  
            50P – – – ND  
            CRC-52 + (H) – + –  
            CRC-54 – A445T – –  
            CRC-55 – – + –  
            CRC-56 – – + –  
            56P – – + ND  
            CRC-59 – – + –  
            59P – – + ND  
            CRC-60 – – – –  
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